2026年欧洲肿瘤内科学会年会（ESMO Congress 2026）将于当地时间10月23—27日在西班牙马德里召开，是全球肿瘤领域顶级学术会议之一。
目前ESMO官方已公布本届会议的口头报告标题及讲者信息。【肿瘤资讯】特梳理Presidential Symposium（主席研讨会）、Proffered Paper Session（优选口头报告）、Rapid Oral Session（快速口头报告）中的LBA研究。其中，肺癌领域LBA共19项（2项暂未公布标题及讲者），中国之声占9项。
Presidential Symposium I
摘要号：LBA3
标题：Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
中文标题： 在广泛期小细胞肺癌（ES-SCLC）中，一线度伐利尤单抗＋铂类＋依托泊苷（1L durva+EP）诱导后，塔拉妥单抗联合度伐利尤单抗对比单用度伐利尤单抗作为一线维持治疗：III期DeLLphi-305试验主要分析
讲者：Jacob Sands (Boston, United States of America)
Presidential Symposium II
摘要号：LBA5
标题：Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC
中文标题：Krascendo 1：在既往治疗过的局部晚期或转移性KRAS G12C突变NSCLC中，divarasib（diva）对比sotorasib（soto）或adagrasib（ada）的疗效与安全性
讲者：Ferdinandos Skoulidis (Houston, United States of America, TX)
摘要号：LBA6
标题：Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results
Shun Lu (Shanghai, China)
中文标题：既往奥希替尼治疗后、EGFR突变且MET过表达和/或扩增的晚期NSCLC中，奥希替尼＋赛沃替尼对比铂类－培美曲塞：SAFFRON III期主要结果
讲者：陆舜 上海市胸科医院
Proffered paper 1: NSCLC, metastatic
摘要号：LBA66
标题：Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study
中文标题：PD-L1阴性晚期非鳞状NSCLC一线治疗：芦康沙妥珠单抗（sac-TMT）联合帕博利珠单抗对比化疗联合帕博利珠单抗：随机III期OptiTROP-Lung06研究
讲者：周彩存 上海市东方医院
摘要号：LBA67
标题：Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study
中文标题：EGFR突变NSCLC在EGFR-TKI治疗进展后，芦康沙妥珠单抗对比含铂化疗的最终OS分析：III期OptiTROP-Lung04研究
讲者：张力 中山大学肿瘤防治中心
摘要号：LBA68
标题：Phase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in previously treated nonsquamous non-small cell lung cancer (NSCLC)
中文标题：既往治疗过的非鳞状NSCLC中，sigvotatug vedotin（SV）对比多西他赛的III期研究
讲者：Solange Peters (Lausanne, Switzerland)
Proffered paper 2: NSCLC, metastatic
摘要号：LBA69
标题：Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study
中文标题：初治、EGFR突变合并MET过表达的晚期NSCLC中，赛沃替尼或安慰剂联合奥希替尼：III期SANOVO研究结果
讲者：吴一龙 广东省人民医院
摘要号：LBA71
标题：PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI
中文标题：PANKU-Lung01：在三代EGFR TKI治疗进展后EGFR突变非鳞状NSCLC中使用伦康依隆妥单抗（iza-bren）的随机III期研究
讲者：张力 中山大学肿瘤防治中心
摘要号：LBA72
标题：Ruzaltatug rezetecan, a HER3-directed ADC, vs platinum-based chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trial
中文标题：靶向HER3的ADC ruzaltatug rezetecan对比含铂化疗，用于EGFR-TKI治疗进展后的EGFR突变晚期NSCLC：III期HERON-Lung01试验中期分析
讲者：吴一龙 广东省人民医院
Proffered paper: Non-metastatic NSCLC and other thoracic malignancies
摘要号：LBA64
标题：Toripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch study
中文标题：特瑞普利单抗联合化疗作为可切除II期或III期NSCLC围手术期治疗：III期Neotorch研究最终分析
讲者：陆舜 上海市胸科医院
Proffered paper 1: Basic science and translational research
摘要号：LBA94
标题：Error-corrected plasma whole-genome sequencing for personalised and tumour-agnostic minimal residual disease detection in TRACERx
中文标题：在TRACERx中采用纠错血浆全基因组测序实现个体化、瘤种无关的微小残留病（MRD）检测
讲者：Jonathan C. Wan (London, United Kingdom)
Rapid oral 1: NSCLC, metastatic
摘要号：LBA73
标题：PACE-LUNG: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment (AIO-TRK-0422/ass)
中文标题：PACE-LUNG：多中心单臂II期临床试验，评估一线奥希替尼治疗第3周时血浆仍可检出EGFR突变ctDNA的EGFRm NSCLC患者追加化疗的疗效（AIO-TRK-0422/ass）
讲者：Martin Sebastian (Frankfurt am Main, Germany)
摘要号：LBA74
标题：First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04)
中文标题：HER2突变NSCLC一线使用德曲妥珠单抗（T-DXd）的患者报告结局（PRO）：来自DESTINY-Lung04（DL-04）
讲者：Silvia Novello (Orbassano, Italy)
摘要号：LBA75
标题：Deulorlatinib (TGRX‑326) vs crizotinib in TKI-naive advanced ALK+ NSCLC: a phase 3 study
中文标题：Deulorlatinib（TGRX-326）对比克唑替尼治疗未接受过TKI治疗的晚期ALK阳性NSCLC：III期研究
讲者：张力 中山大学肿瘤防治中心
Rapid oral 2: NSCLC, metastatic
摘要号：LBA76
标题：A global phase 2, open-label trial of pumitamig (PD-L1 × VEGF-A bsAb) + docetaxel post-chemoimmunotherapy in mNSCLC: first data from ROSETTA Lung-107
中文标题：转移性NSCLC在化疗免疫治疗后采用pumitamig（PD-L1×VEGF-A双特异性抗体）＋多西他赛的全球II期开放标签试验ROSETTA Lung-107首批数据
讲者：Byoung Chul Cho (Seoul, Republic of Korea)
Rapid oral: Non-metastatic NSCLC and other thoracic malignancies
摘要号：LBA62
标题：ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE
中文标题：MDT-BRIDGE研究中，可切除/临界可切除IIB–IIIB期NSCLC新辅助治疗期间ctDNA清除及其与临床结局的关联
讲者：Jonathan Spicer (Montreal, Canada)
摘要号：LBA65
标题：Surgical Conversion and Survival Outcomes After Induction Chemoimmunotherapy in Potentially Resectable or Unresectable Stage III NSCLC: Preliminary Results from the Prospective Phase II Study (CTONG 1804 Part 3).
中文标题：潜在可切除或不可切除III期NSCLC诱导化疗免疫治疗后手术转化及生存结局：前瞻性II期CTONG 1804第3部分初步结果
讲者：潘燚 广东省人民医院
（官网持续更新中，如有疏漏，欢迎补充）
排版编辑：肿瘤资讯-TY
苏公网安备32059002004080号
